Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
By Waleed Haso, Daniel W. Lee, N. Shah, M. Stetler-Stevenson, C. Yuan, I. Pastan, Dimiter S. Dimitrov, R. Morgan, D. FitzGerald, D. Barrett and 3 more. 2013
560 citations recorded by the source corpus.
Subfields: Immunology, Oncology, Public Health, Environmental and Occupational Health
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Tumor Antigen Escape from CAR T-cell Therapy. (2018, methodology): “In recognizing that single antigen targeting was unlikely to be successful in many cases of pediatric B-ALL, we developed a CAR targeting CD22, another B-cell antigen broadly expressed on lymphoblasts (63).”
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses (2018, unknown): “Also, CD22 and CD123 CARs have been recently developed to increase tumor specificity (Haso et al., 2013; Ruella et al., 2016).”
- CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL (2017, unknown): “18 Like CD19, CD22 is expressed on most cases of pre-B cell ALL 14,19,20 , and normal tissue expression is restricted to the B cell lineage.”
- CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice (2021, methodology): “It has been indicated that CARs targeting membrane-proximal epitopes may have better antitumor activity than those incorporating membrane-distal binding domains.(18,19) Thus, we immunized mice using the C-terminal region (exon 10) of GPC2 and isolated mAbs with membrane-proximal GPC2specific epitope”
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. (2015, background): “Additional B cell-specific cell surface molecules, such as CD22, may hold similar promise and are under active investigation.(40)”